1. 177Lu-DOTA-HYNIC-Lys(Nal)-Urea-Glu: synthesis and assessment of the ability to target the prostate specific membrane antigen.
- Author
-
Hernández-Jiménez, Tania, Ferro-Flores, Guillermina, Ocampo-García, Blanca, Morales-Avila, Enrique, Escudero-Castellanos, Alondra, Azorín-Vega, Erika, Santos-Cuevas, Clara, Luna-Gutiérrez, Myrna, Jiménez-Mancilla, Nallely, Medina, Luis Alberto, Ramirez, Flor de Maria, and Pedraza-López, Martha
- Subjects
- *
CANCER diagnosis , *PROSTATE-specific membrane antigen , *PROSTATE cancer treatment , *RADIOACTIVE tracers , *MOLECULAR probes - Abstract
SPECT/CT images have proved the capability of 99mTc-EDDA/HYNIC-Lys(β-naphthylalanine)-NH-CO-NH-Glu to detect prostate cancer tumors in patients. Considering that theranostics combines the potential of therapeutic and diagnostic radionuclides in the same molecular probe, this research aimed to prepare 177Lu-DOTA-HYNIC-Lys(β-naphthylalanine)-NH-CO-NH-Glu (177Lu-iPSMA) and evaluate the in vitro and in vivo radiotracer ability to target the PSMA protein overexpressed in prostate cancer cells (LNCaP). 177Lu-iPSMA, obtained with radiochemical purities of 99%, showed specific in vitro and in vivo recognition for PSMA in prostate cancer cells and high LNCaP-tumor uptake (11 ± 2% ID/g at 24 h). The results obtained warrant further studies to evaluate the therapeutic efficacy of 177Lu-iPSMA. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF